Alternative therapy use and adherence to antihyperlipidemic drugs in a lipid clinic

American Journal of Health-System Pharmacy

Volumn 58, Issue 11, 2001, Pages 1017-1021

  O'Donnell, Dannielle C ^a,b,c   Brown, Carolyn M ^d   Piziak, Veronica K ^b,e  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Division of Pharmacy Practice and Administration   (United States)

^e Scott White Mem Hosp and Clinics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; CHROMIUM; FISH OIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; UBIDECARENONE;

ADULT; AGED; AGING; ALTERNATIVE MEDICINE; DEMOGRAPHY; DYSLIPIDEMIA; FEMALE; GARLIC; HEALTH CENTER; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0035370001     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.11.1017     Document Type: Note

References (26)

1. 1998 Heart and stroke statistical update. Dallas: American Heart Association; 1997.
2. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995; 333:1301-7.
3. Downs JR, Clearfield M, Weiss S et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998; 279:1615-22.
4. Sacks FM, Pfeiffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-9.
5. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simva-statin Survival Study (4S). Lancet. 1994; 344:1383-9.
6. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998; 339:1349-57.
7. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994; 89:1329-45.
8. Fix K, Oberman A. Barriers to following National Cholesterol Education Program guidelines (an appraisal of poor physician compliance). Arch Intern. Med. 1992; 152:2385-7.
9. Schrott H, Bittner V, Vittinghoff E et al. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease (the Heart and Estrogen/Progestin Replacement Study - HERS). JAMA. 1997; 277:1281-6.
10. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med. 1996; 100:197-204.
11. McKenney J. The cost of treating dyslipidemia using National Cholesterol Education Program (NCEP) guidelines. Pharmacoeconomics. 1998; 4(suppl 3): 19-28.
12. Andrade SE, Walker AM, Gottlieb LK et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332:1125-31.
13. Sung JCY, Nichol MB, Venturini F et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care. 1998; 4:1421-30.
14. Brown CM, Segal R. The effects of health and treatment perceptions on the use of prescribed medication and home remedies among African American and white American hypertensives. Soc Sci Med. 1996; 43:903-17.
15. Bennett G, Brown CM. Use of herbal remedies by patients in a health maintenance organization. J Am Pharm Assoc. 2000; 40:353-8.
16. Astin J A. Why patients use alternative medicine: results of a national study. JAMA. 1998; 279:1548-53.
17. Elder NC. Use of alternative health care by family practice patients. Arch Fam Med. 1997; 6:181-4.
18. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997. JAMA. 1998; 280:1569-75.
19. Tanne JH. US spends more than 16bn on alternative remedies. BMJ. 1998; 317: 1408. News.
20. Eisenberg DM, Kessler RC, Foster C et al. Unconventional medicine in the United States: prevalence, costs and patterns of use. N Engl J Med. 1993; 328: 246-52.
21. O'Donnell DC, Chen NTW, Piziak VK. LDL-cholesterol goal attainment and maintenance by patients referred to a pharmacist-coordinated lipid clinic. Am J Health-Syst Pharm. 2001; 58:325-30.
22. Hershey JC, Morton BG, Davis JB et al. Patient compliance with antihypertensive medication. Am J Public Health. 1980; 70:1081-9.
23. Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Arch Intern Med. 1995; 155:2330-5.
24. Harris DE, Record NB, Gipson GW et al. Lipid lowering in a multidisciplinary clinic compared with primary physician management. Am J Cardiol. 1998; 81: 929-33.
25. Druss BG, Rosenheck RA. Association between use of unconventional therapies and conventional medical services. JAMA. 1999; 282:651-6.
26. Kravitz RL, Hays RD, Sherbourne CD et al. Recall of recommendations and adherence to advice among patients with chronic medical conditions. Arch Intern Med. 1993; 153:1869-78.